Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis

Schizophrenia Research

Volumn 138, Issue 2-3, 2012, Pages 206-211

  Lavoie, Suzie ^a   Schäfer, Miriam R ^a,b   Whitford, Thomas J ^c,d   Benninger, Franz ^b   Feucht, Martha ^e   Klier, Claudia M ^e   Yuen, Hok Pan ^a   Pantelis, Christos ^c   McGorry, Patrick D ^a   Amminger, G Paul ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

Omega 3; Polyunsaturated fatty acids; Psychosis; Resting EEG; Spectral analyses; Ultra high risk

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BRAIN REGION; CLINICAL FEATURE; CONTROLLED STUDY; DELTA RHYTHM; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FREQUENCY MODULATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; DELTA RHYTHM; DISEASE PROGRESSION; ELECTROENCEPHALOGRAPHY; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RISK FACTORS; YOUNG ADULT;

EID: 84862128104     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.03.033     Document Type: Article

References (29)

1. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
2. Appleton K.M., Rogers P.J., Ness A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 2010, 91(3):757-770.
3. Aurlien H., Gjerde I.O., Aarseth J.H., Eldoen G., Karlsen B., Skeidsvoll H., Gilhus N.E. EEG background activity described by a large computerized database. Clin. Neurophysiol. 2004, 115(3):665-673.
4. Berger G.E., Wood S.J., Wellard R.M., Proffitt T.M., McConchie M., Amminger G.P., Jackson G.D., Velakoulis D., Pantelis C., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008, 33:2467-2473.
5. Boutros N.N., Arfken C., Galderisi S., Warrick J., Pratt G., Iacono W. The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophr. Res. 2008, 99(1-3):225-237.
6. Dustman R.E., Shearer D.E., Emmerson R.Y. Life-span changes in EEG spectral amplitude, amplitude variability and mean frequency. Clin. Neurophysiol. 1999, 110(8):1399-1409.
7. Fontani G., Corradeschi F., Felici A., Alfatti F., Migliorini S., Lodi L. Cognitive and physiological effects of omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur. J. Clin. Invest. 2005, 35(11):691-699.
8. Freeman M.P., Mischoulon D., Tedeschini E., Goodness T., Cohen L.S., Fava M., Papakostas G.I. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J. Clin. Psychiatry 2010, 71(6):682-688.
9. Galderisi S., Mucci A., Volpe U., Boutros N. Evidence-based medicine and electrophysiology in schizophrenia. Clin. EEG Neurosci. 2009, 40(2):62-77.
10. Gattaz W.F., Mayer S., Ziegler P., Platz M., Gasser T. Hypofrontality on topographic EEG in schizophrenia. Correlations with neuropsychological and psychopathological parameters. Eur. Arch. Psychiatry Clin. Neurosci. 1992, 241(6):328-332.
11. Gomez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat. Rev. Neurosci. 2008, 9(7):568-578.
12. Gschwandtner U., Zimmermann R., Pflueger M.O., Riecher-Rossler A., Fuhr P. Negative symptoms in neuroleptic-naive patients with first-episode psychosis correlate with QEEG parameters. Schizophr. Res. 2009, 115(2-3):231-236.
13. Guenther W., Davous P., Godet J.L., Guillibert E., Breitling D., Rondot P. Bilateral brain dysfunction during motor activation in type II schizophrenia measured by EEG mapping. Biol. Psychiatry 1988, 23(3):295-311.
14. Guich S.M., Buchsbaum M.S., Burgwald L., Wu J., Haier R., Asarnow R., Nuechterlein K., Potkin S. Effect of attention on frontal distribution of delta activity and cerebral metabolic rate in schizophrenia. Schizophr. Res. 1989, 2(6):439-448.
15. Harris A.W., Williams L., Gordon E., Bahramali H., Slewa-Younan S. Different psychopathological models and quantified EEG in schizophrenia. Psychol. Med. 1999, 29(5):1175-1181.
16. Ingvar D.H., Sjolund B., Ardo A. Correlation between dominant EEG frequency, cerebral oxygen uptake and blood flow. Electroencephalogr. Clin. Neurophysiol. 1976, 41(3):268-276.
17. Knyazev G.G. EEG delta oscillations as a correlate of basic homeostatic and motivational processes. Neurosci. Biobehav. Rev. 2012, 36(1):677-695.
18. Lundbaek J.A., Collingwood S.A., Ingolfsson H.I., Kapoor R., Andersen O.S. Lipid bilayer regulation of membrane protein function: gramicidin channels as molecular force probes. J. R. Soc. Interface 2010, 7(44):373-395.
19. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 2005, 62(9):975-983.
20. McGorry P.D., Killackey E., Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008, 7(3):148-156.
21. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., Parker S., Bentall R.P. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004, 185:291-297.
22. Pantelis C., Yucel M., Bora E., Fornito A., Testa R., Brewer W.J., Velakoulis D., Wood S.J. Neurobiological markers of illness onset in psychosis and schizophrenia: the search for a moving target. Neuropsychol. Rev. 2009, 19(3):385-398.
23. Pollock V.E., Schneider L.S. Quantitative, waking EEG research on depression. Biol. Psychiatry 1990, 27(7):757-780.
24. Rocha Araujo D.M., Vilarim M.M., Nardi A.E. What is the effectiveness of the use of polyunsaturated fatty acid omega-3 in the treatment of depression?. Expert. Rev. Neurother. 2010, 10(7):1117-1129.
25. Sumich A., Matsudaira T., Gow R.V., Ibrahimovic A., Ghebremeskel K., Crawford M., Taylor E. Resting state electroencephalographic correlates with red cell long-chain fatty acids, memory performance and age in adolescent boys with attention deficit hyperactivity disorder. Neuropharmacology 2009, 57(7-8):708-714.
26. Uhlhaas P.J., Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 2010, 11(2):100-113.
27. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60(1):21-32.
28. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 2005, 39(11-12):964-971.
29. Zimmermann R., Gschwandtner U., Wilhelm F.H., Pflueger M.O., Riecher-Rossler A., Fuhr P. EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophr. Res. 2010, 123(2-3):208-216.